Home
Conditions
Refractory Mantle Cell Lymphoma

Clinical trial condition

Refractory Mantle Cell Lymphoma

Explore clinical trials studying Refractory Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

41 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

Refractory Mantle Cell Lymphoma trial results

Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

NCT07003295

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

Emory University Hospital Midtown Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

Emory Saint Joseph's Hospital Atlanta, Georgia, United States

View Trial Details

Recruiting

Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

NCT07673367

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States

View Trial Details

Recruiting

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT06675123

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT06839053

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +25 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06859008

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +39 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887

Conditions: B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
Locations: Mayo Clinic in Florida Jacksonville, Florida, United States

View Trial Details

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04484012

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

View Trial Details

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Not yet recruiting

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07578077

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800

Conditions: Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Refractory Mantle Cell Lymphoma

Refractory Mantle Cell Lymphoma trial results

Related conditions